Germany is no longer “the world’s pharmacy”. Government interventions, such as mandatory discounts, controlled prices and re-importation policies, are challenges for a globalized industry, where innovation and medical progress go hand-in-hand with increasing demands on time and funding for research and development.
In addition to their current business areas, many companies seek to explore new markets – e.g., by concentrating on generic drugs or by specializing within certain market niches. Strategic cooperation’s of pharmaceutical companies with medical engineering or biotechnology companies are gaining importance. Price erosion, increasing self-medication, OTC sales, and new distribution channels have led to drastically changed sales structures.
In addition to the traditional business areas, many companies are interested in exploring new markets – for example through diversification, verticalization or specialization. Cooperation’s between pharmaceutical, medical technology and biotechnology companies is just as important as innovative contracts with health insurance funds and more patient-centered care.
Together, we will create sustainable concepts that will not only help you to consolidate your company and to explore new markets but also to adjust your organization and processes. We place special importance on practical feasibility and provide intensive guidance throughout the implementation process, along with stringent change management.